Cadila Healthcare’s arm settles patent litigation with Aptalis on CANASA

14 Aug 2017 Evaluate

Cadila Healthcare’s subsidiary Zydus Pharmaceuticals (USA) Inc., a leading generic pharmaceutical company in the United States, has settled the patent litigation relating to Aptalis’s CANASA (mesalamine suppository, 1 g). As a result of the settlement, Zydus Pharmaceuticals (USA) Inc., will be able to market its generic version of CANASA in the United States beginning on June 13, 2019, or earlier under certain circumstances.

Zydus Cadila previously received tentative approval from the USFDA to market its generic version of CANASA (mesalamine suppository, 1 g). CANASA is indicated to treat mildly to moderately active ulcerative colitis. Zydus Cadila’s generic product will be produced at the group’s Topical plant at Ahmedabad.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

893.45 11.50 (1.30%)
27-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.30
Dr. Reddys Lab 1240.00
Cipla 1312.85
Zydus Lifesciences 893.45
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×